Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Freedom Investment Management Inc.

Freedom Investment Management Inc. reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 19.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 11,011 shares of the biopharmaceutical company's stock after selling 2,713 shares during the period. Freedom Investment Management Inc.'s holdings in Gilead Sciences were worth $1,017,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Westside Investment Management Inc. lifted its position in shares of Gilead Sciences by 3.5% during the third quarter. Westside Investment Management Inc. now owns 27,443 shares of the biopharmaceutical company's stock worth $2,249,000 after purchasing an additional 917 shares in the last quarter. SkyView Investment Advisors LLC lifted its holdings in Gilead Sciences by 5.4% during the 3rd quarter. SkyView Investment Advisors LLC now owns 8,482 shares of the biopharmaceutical company's stock worth $711,000 after buying an additional 435 shares in the last quarter. Pine Valley Investments Ltd Liability Co purchased a new position in Gilead Sciences in the 3rd quarter valued at approximately $209,000. World Investment Advisors LLC grew its stake in shares of Gilead Sciences by 33.6% in the third quarter. World Investment Advisors LLC now owns 25,999 shares of the biopharmaceutical company's stock worth $2,180,000 after acquiring an additional 6,535 shares in the last quarter. Finally, Arvest Bank Trust Division purchased a new stake in shares of Gilead Sciences during the third quarter worth $9,661,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Analyst Ratings Changes

Several research analysts recently commented on GILD shares. Wells Fargo & Company boosted their target price on Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Piper Sandler upped their target price on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and lifted their price target for the stock from $80.00 to $120.00 in a research note on Tuesday, February 18th. The Goldman Sachs Group increased their price objective on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research report on Wednesday, February 12th. Finally, Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a report on Wednesday, February 12th. Ten research analysts have rated the stock with a hold rating, sixteen have given a buy rating and four have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $106.92.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $104.09, for a total value of $260,225.00. Following the sale, the chief financial officer now owns 169,061 shares of the company's stock, valued at approximately $17,597,559.49. This represents a 1.46 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 302,785 shares of company stock worth $30,540,875 over the last 90 days. Company insiders own 0.27% of the company's stock.

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD traded down $0.17 during midday trading on Wednesday, hitting $105.34. The stock had a trading volume of 3,343,824 shares, compared to its average volume of 7,495,909. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $119.96. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The stock has a 50 day moving average price of $109.17 and a two-hundred day moving average price of $97.82. The company has a market capitalization of $131.17 billion, a PE ratio of 284.70, a P/E/G ratio of 0.71 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, equities analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 3.00%. The ex-dividend date was Friday, March 14th. This is an increase from Gilead Sciences's previous quarterly dividend of $0.77. Gilead Sciences's dividend payout ratio (DPR) is currently 854.05%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.